CareDx Reports Strong Q3 Financial Results

CareDx ( (CDNA) ) has shared an announcement.

On November 4, 2025, CareDx announced its third-quarter financial results, highlighting a 21% year-over-year revenue increase to $100.1 million, driven by a 19% rise in testing services revenue and a 13% growth in testing services volume. The company reported a GAAP net income of $1.7 million, a significant improvement from the previous year’s loss, and raised its 2025 revenue guidance to $372 million to $376 million. Recent strategic moves include appointing new leadership, publishing studies, and launching innovative products, reinforcing its market leadership in transplant care.

The most recent analyst rating on (CDNA) stock is a Hold with a $15.50 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.

Spark’s Take on CDNA Stock

According to Spark, TipRanks’ AI Analyst, CDNA is a Neutral.

CareDx’s overall stock score reflects a mixed financial performance with profitability but declining revenue and cash flow growth. Technical analysis shows stability, and valuation is reasonable. The earnings call provided positive growth indicators, but potential policy impacts and revenue write-offs pose risks.

To see Spark’s full report on CDNA stock, click here.

More about CareDx

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.

Average Trading Volume: 1,323,724

Technical Sentiment Signal: Sell

Current Market Cap: $786.2M

For detailed information about CDNA stock, go to TipRanks’ Stock Analysis page.